Patent · US Active

N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimetic

US8865865B2 · kind B2 · utility

0Cited by

1References

3Claims

0Family size

Assignee

Philipps-Universitat Marburg · DE

Inventors

Torsten Steinmetzer · Jena, DE
Gero Becker · Marburg, DE
Wolfgang Garten · Gießen, DE

Key dates

Filing date	Oct 29, 2009
Grant date	Oct 21, 2014
Priority date	—
Expiry date	Oct 29, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention refers to multibasic, N-terminally modified tetrapeptide mimetics with a C-terminal P1-arginine mimetic, methods for their production and use for therapy and prophylaxis of diseases, caused by bacterial pathogens or viruses, as well as for therapy and prophylaxis of diabetes, arteriosclerosis, cancer, Alzheimer's or the onset of obesity, as well as the use of these compounds as inhibitors of the proprotein convertases which cleave behind basic P1 residues, especially for inhibition of the protease furin.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.